Skip to content

Efficacy of anti-coagultion, lipolytic and anti-inflammatory phytotherapeutic agents for the treatment of osteoarthritis

Efficacy of anti-coagultion, lipolytic and anti-inflammatory phytotherapeutic agents for the treatment of osteoarthritis

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12605000630617
Acronym
BR95628
Enrollment
80
Registered
2005-10-12
Start date
1996-04-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Active (400mg Garlic, 40mg Ginkgo and 250mg Devils Claw) one tablet three time daily, for 12 weeks.

Sponsors

Blackmores Ltd
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Subjects with a diagnosis of painful OA of the hip or knee, with or without other joint involvment, as defined by:i) hip or knee pain while standing, walking and/or in motion of at least 3 months duration, and ii) evidence of one or more of the following features in an X-ray picture taken in the past 6 months: osteophytes, cysts or joint space narrowingSubjects with profiles defined by (Triglycerides > 1mmol/L and (ECLT (euglobulin clot lysis time) >190min or Cholesterol >5.9mmol/L)) or (Diastolic blood pressure >85mmHg and <110mmHg).Subjects willing to discontinue their current OA treatment for the study duration, commencing 2 weeks pripor to their first visit (29 weeks).

Exclusion criteria

History of joint replacementSurgery on the knee or hip within the past 12 months or arthroscopy within the past 6 months.Adminstration of any long-acting osteoarthritis therapy in the previous 3 months.Subjects will contra-indications to the study medication or to paracetamol (inlcuding allergies)Subjects with a Diastolic blood pressure of >=100mmHg or systolic blood pressure >= 180mmHg at any stage of the studySubjects on any medication known to interact with anti-hypertensive or lipid lowering drugs or to influence platelet function.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026